Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ER discharge plan aims to stop opioid overdose deaths

NCT ID NCT07485335

Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of telehealth, peer support, and medication (buprenorphine) to help people with opioid use disorder stay in treatment after leaving the emergency room. The goal is to reduce repeat overdoses and prevent deaths. About 160 adults who have had an opioid overdose in the past year and are prescribed buprenorphine in the ER will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. discharged from the ED and inpatient settings at the UAB hospital 2. 19 years or older (the age of majority in Alabama); 3. diagnosis of OUD and experiencing opioid overdose in the last 12 months; 4. prescribed buprenorphine in the ED and willing to continue buprenorphine post-ED discharge; 5. English speaking; 6. not actively psychotic and suicidal, or cognitively impaired. 7. Patients who are admitted to the hospital from the ED will be eligible for enrollment. Exclusion Criteria: 1. living in a restricted environment (e.g., prison or jail facility, etc.); 2. currently enrolled in other clinical studies; 3. anticipated to take other prescribed opioids except buprenorphine for a medical condition longer than three months; 4. known allergic reaction to buprenorphine; 5. critically ill or injured; 6. females with pregnancy (they are anticipated to request a higher level of care). 7. living outside of Alabama

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid overdose are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute opioid poisoning Emergencies opiate dependence Opiate Overdose

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid overdose Opioid-use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UAB

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.